Skip to content
    AVTR
    Earnings call· Jun 2026(Q2 FY26)

    Avantor Q2 FY26 earnings call AVTR

    Jul 29, 2026 Source

    Executive summary

    Avantor Q2 FY26 — VWR Returns to Growth, Raised Full-Year Guidance

    Avantor's Q2 FY26 results exceeded expectations, primarily driven by the VWR segment's earlier-than-anticipated return to 1.7% organic growth, fueled by strategic actions and digital enhancements. The Bioscience & Medtech Products (BMP) segment, while down organically, showed strong order intake and is poised for a second-half recovery. The company raised its full-year organic revenue and adjusted EPS guidance, reflecting improved performance and confidence in its "Revival" program, which focuses on operational excellence and debt reduction.

    Highlights

    5

    • VWR Distribution & Service segment returned to positive organic revenue growth of 1.7% in Q2 FY26, ahead of expectations.

    • Adjusted EBITDA grew over 15% sequentially from Q1, driven by increased volumes.

    • Generated strong free cash flow of $152 million (excluding restructuring costs) in Q2 FY26, used to repay $112 million of debt.

    • Raised full-year 2026 organic revenue growth guidance to -0.5% to +0.5% and adjusted EPS guidance to $0.80-$0.83.

    • BMP segment delivered double-digit order growth and a book-to-bill ratio of 1.1x in Q2 FY26, indicating future growth.

    Concerns

    5

    • BMP revenue declined 5.6% organically in Q2 FY26, impacted by discrete factors and difficult comparisons.

    • VWR's adjusted operating margin declined year-over-year due to mix and inflationary pressures.

    • Foreign exchange is expected to be a headwind of about 50 basis points to full-year revenue and 125 basis points to Q3 reported revenue.

    • Activity levels in end markets like education and certain European geographies remain stable but at lower levels than desired.

    • BMP faces a headwind of about 150 basis points to organic growth in Q3 FY26 from discrete customer ordering patterns and shipments.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year 2026 Organic Revenue Growth
    negative 0.5% to positive 0.5%
    high materiality
    High
    Full-year 2026 Adjusted EPS
    $0.80 to $0.83
    high materiality
    High
    Full-year 2026 Adjusted EBITDA Margin
    unchanged
    medium materiality
    High
    Full-year 2026 Free Cash Flow
    $500 million and $550 million
    high materiality
    High
    Q3 2026 Adjusted EPS
    $0.20 and $0.21 per share
    medium materiality
    High
    Q3 2026 Total Company Organic Revenue Growth
    about 250 basis points
    medium materiality
    High
    Q3 2026 FX Headwind to Reported Revenue
    about 125 basis points
    medium materiality
    High
    BMP Organic Growth
    return to growth
    high materiality
    High
    VWR Organic Growth
    accelerate
    high materiality
    High
    Adjusted Net Leverage Ratio
    below 3x
    high materiality
    High
    Net Interest Expense
    decline modestly
    low materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    VWR Distribution & Services
    Returned to growth ahead of expectations, driven by increased volumes from strong commercial execution, improved performance with large global customers, and better e-commerce outcomes for small/midsized customers. Margins increased approximately 100 basis points sequentially from Q1 due to increased volumes and improved mix. Pharma and biotech customer activity provided a modest tailwind.
    Adjusted operating income: $126 million
    		$1.24 billion1.7% organically—10.2% adjusted operating margin
    Bioscience & MedTech Products
    Revenue was near the high end of expectations, with solid performance across product lines. Process Chemicals grew faster than expectations. Fluid Handling and NuSil were down mid-teens, and Research and Specialty Chemicals declined mid-single digits. Discrete factors (customer ordering patterns, shipments in 2025) and difficult comparisons (Fluid Handling) represented a 600 basis point headwind to organic growth. Margins increased sequentially due to increased volumes and mix. Order trends were healthy across all business units, with particular strength in Process Chemicals and Fluid Handling.
    Adjusted operating income: $118 millionBook-to-bill ratio: 1.1xOrder growth: double-digit
    		$452 million-5.6% organically—26% adjusted operating margin

    Operational metrics

    15
    Total Revenue
    $1.69 billionup 0.5% reported, down 0.4% organic
    Q2 FY26

    Stronger than anticipated, driven primarily by VWR.

    Adjusted EBITDA
    $254 milliongrew more than 15% sequentially from Q1
    Q2 FY26

    Driven by increased volumes in both segments.

    Adjusted EPS
    $0.21above expectations
    Q2 FY26
    Debt Repayment
    $112 millionnearly $500 million over trailing 12 months
    Q2 FY26

    Used strong cash generation to further strengthen the balance sheet.

    Adjusted Net Leverage Ratio
    3.3xflat sequentially
    Q2 FY26 end

    Moody's revised ratings outlook to positive.

    Headcount
    down approximately 3%vs beginning of year
    YTD FY26

    Reflects focus on cost discipline.

    Manufacturing Throughput
    more than 25%vs Q1 FY26
    Q2 FY26

    Direct result of Revival initiatives, including Lean and Six Sigma tools.

    Customer Onboarding Completion Time
    from up to 4 days to as little as 2 daysfrom prior process
    current

    Redesigned process for complex accounts, down to minutes for simple accounts.

    FX Impact on Revenue
    about 50 basis points
    FY26

    Expected headwind to reported revenue due to recent strength of the U.S. dollar.

    BMP Organic Growth Headwind
    about 150 basis points
    Q3 FY26
    BMP Organic Growth Headwind
    about 400 basis points
    Q4 FY26
    Net Debt
    $3.4 billion
    Q2 FY26 end
    Weighted Average Diluted Share Count
    677 million
    FY26

    Assumption for full-year guidance.

    Adjusted Operating Income
    $126 million
    Q2 FY26
    Adjusted Operating Income
    $118 million
    Q2 FY26

    Industry KPIs

    7
    MetricValueDetails
    FCF conversion ROIC—
    Revenue EPS guidanceOrganic Revenue Growth: -0.5% to +0.5%; Adjusted EPS: $0.80 to $0.83% for revenue, USD for EPS
    Pricing price realization—
    Segment organic revenue growthVWR: 1.7%; BMP: -5.6%%
    Bioprocessing orders book to bill1.1x
    Instruments vs consumables services mix—
    Organic core revenue growth by end market—

    Risks & headwinds

    4
    Foreign Exchange Headwindsecond half of 2026 and Q3 FY26

    about 50 basis points to full year revenue and about 125 basis points to Q3 reported revenue

    Mitigation: operational outperformance enables us to absorb macro inflationary pressures

    Inflationary Pressuresongoing

    significant pressure on freight costs for both segments

    Mitigation: operational outperformance enables us to absorb macro inflationary pressures while also making targeted growth investments; successfully navigate inflationary pressures with our customers and suppliers constructively

    Lower Activity in Education and European End MarketsQ2 FY26 and ongoing

    stable, but at a lower level than we would love to see

    Mitigation: An improvement in those end markets could represent an additional tailwind to our growth.

    Discrete Headwinds in BMPQ2, Q3, Q4 FY26

    600 basis points to BMP organic revenue growth in the second quarter and about 150 basis points to organic growth in Q3 and about 400 basis points related to our electronic materials business in Q4.

    Mitigation: improved execution and more favorable discrete comparisons in H2; gradual strengthening in the volumes over the course of the year

    What to watch in Q3 FY26

    5

    VWR Organic Revenue Growth Acceleration

    H2 FY26
    Current1.7% organic growth in Q2 FY26
    Targetaccelerated growth

    Why it matters

    VWR's sustained acceleration is key to overall company growth and validates the effectiveness of the Revival program's commercial and digital initiatives.

    We continue to expect growth to accelerate through the remainder of the year.

    Q&A highlights

    6

    How much of VWR's Q2 growth was due to company actions vs. market recovery, and how much of the guidance raise is attributable to each? Also, quantify the headwind from past contract renewals.

    Emmanuel Ligner stated that over half of VWR's Q2 growth came from deliberate actions, including successful new contract wins and increased share of wallet with large global customers, as well as positive impact from the relaunched vwr.com for smaller customers. The remainder was from improved pharma/biotech end markets. He declined to quantify the exact headwind from past contract renewals but noted they are now lapping those pressures.

    “more than half of the growth that we deliberated in Q2 comes from deliberated action that we're taking.”

    asked by Eve Burstein · answered by Emmanuel Ligner

    2 min read5 chapters

    Detailed Narrative

    01

    Revival Program Driving Performance

    Avantor's "Revival" program, launched nearly 12 months ago, is yielding measurable results, contributing to the company's improved Q2 performance. This comprehensive program, built on five pillars including commercial excellence and operational performance, has led to significant improvements such as the relaunch of vwr.com, enhanced customer engagement, and increased throughput in key manufacturing lines by over 25% versus Q1. The program's initiatives are credited with VWR's return to growth and BMP's strong order intake.

    02

    VWR's Broad-Based Momentum

    The VWR Distribution & Services segment returned to 1.7% organic growth in Q2, ahead of expectations, driven by deliberate actions rather than just market recovery. Key drivers include stronger performance with large global customers due to successful contract renewals and increased share of wallet, and improved growth in small and mid-sized customer segments through digital enhancements like the relaunched vwr.com. The company expects this momentum to accelerate in the second half of the year.

    03

    BMP's Path to Recovery

    The Bioscience & MedTech Products (BMP) segment, while experiencing a 5.6% organic decline in Q2 due to discrete factors and difficult comparisons, demonstrated strong commercial performance with double-digit order growth and a 1.1x book-to-bill ratio. Management is confident that BMP will return to organic growth in the second half of 2026, supported by improving operations, a healthy order book across all business units (especially Process Chemicals and Fluid Handling), and more favorable year-over-year comparisons.

    04

    Strategic Capital Allocation and Debt Reduction

    Avantor continues to generate strong free cash flow, with $152 million (excluding restructuring costs) in Q2, which is being prioritized for purposeful investments in the business and debt repayment. The company repaid $112 million of debt in the quarter, bringing its adjusted net leverage ratio to 3.3x. Management remains committed to reducing this ratio to below 3x by the end of FY26, a target supported by continued debt paydown and anticipated adjusted EBITDA growth.

    05

    Digital Transformation and Customer Engagement

    A significant focus of the Revival program is digital transformation, particularly within the VWR segment. The relaunch of vwr.com and continuous platform upgrades have positively impacted customer engagement, driving direct traffic, higher conversion rates, and improved daily sales, especially among smaller, higher-margin customers. While progress is encouraging, the company views its digital transformation as being in early stages, with substantial opportunities for further enhancement and sustained growth, particularly in Europe.

    AI-generated summary of the company’s earnings call. Not investment advice.